###### Core evidence clinical impact summary for vinflunine in advanced and metastatic urothelial carcinoma

  Outcome measure             Evidence                                                 Implication
  --------------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease-oriented evidence   Clinical trials and retrospective analyses               Vinflunine when administered as second-line treatment for stage IV UC demonstrated modest gains in tumor response rate and survival
  Patient-oriented evidence   Clinical trials and retrospective analyses               Risk of severe AEs must be weighed carefully against the modest survival benefit of VIN in advanced UC. However, most AEs are preventable or treatable
  Economic evidence           Multicenter, observational, retrospective cohort study   VIN median treatment costs are €13,096 per patient, €44,789 per progression-free year gained, and €22,750 per life-year granted

Introduction
============

Metastatic urothelial carcinoma (UC) is an aggressive and highly lethal cancer despite many patients having an initial response to current systemic cytotoxic therapies. Current first-line treatment for advanced UC consists of platinum-based combination chemotherapy regimens. Of these, cisplatin-based combinations have demonstrated the most favorable overall survival (OS) -- 12--15 months approximately -- and are widely considered the standard of care.[@b1-ce-13-001] Patients who are cisplatin ineligible, most often due to renal insufficiency or neurological disease, traditionally received carboplatin-based combination regimens which, although more tolerable, appear to have worse survival outcomes and are therefore considered less effective.[@b2-ce-13-001] Most patients receiving platinum regimens for metastatic UC will ultimately progress, and many will be offered second-line systemic therapy. Recently, PD-L1 and PD-1 immune checkpoint inhibitors have been approved by the US Food and Drug Administration (FDA) for second-line treatment of advanced UC and for patients in first line who are cisplatin ineligible.

In 2009, the European Medical Association approved vinflunine (VIN), the newest member of the vinca alkaloid family, as a second-line therapy for advanced UC after platinum failure. This drug prevents microtubule assembly during mitosis, inducing apoptosis.[@b3-ce-13-001],[@b4-ce-13-001] Early European Phase II trials in platinum-refractory metastatic UC examined the activity of VIN in 51 and 175 patients showing a response rate of 18% and 15%, respectively, with median progression-free survival (PFS) and OS of 3.0 and 6.6 months in the first study and 2.8 and 8.2 months in the second study.[@b5-ce-13-001],[@b6-ce-13-001] These results led to a pivotal, multicenter Phase III randomized controlled trial by Bellmunt et al comparing VIN plus best supportive care (BSC) to BSC alone in platinum-refractory advanced UC.[@b7-ce-13-001],[@b8-ce-13-001] This trial of 370 patients receiving second-line VIN showed a modest survival benefit of 2.3 months above BSC alone. The FDA has not approved VIN for treatment of advanced UC at this time.

JASiMA, a small 20-patient international Phase II trial, examined response data in patients with advanced UC receiving maintenance VIN immediately following gemcitabine--cisplatin first-line therapy and showed enhanced response in 5 patients (27.8%).[@b9-ce-13-001] MAJA, a placebo-controlled Phase II trial, examined maintenance VIN versus BSC in a larger cohort (88) of patients with platinum-responsive advanced UC and found improved PFS of 6.5 months in the VIN arm versus 4.6 months in BSC arm (HR 0.56, 95% CI 0.34--0.93, *p*=0.024).[@b10-ce-13-001]

The JASINT1 international Phase II trial examined first-line VIN combination therapy with either vinflunine--gemcitabine (VG) or vinflunine--carboplatin (VC) in 69 patients with advanced UC who were ineligible to receive cisplatin. This study found similar disease control rates (DCRs), overall response rates (ORRs), and OS between the 2 groups.[@b11-ce-13-001] Lastly, the IMvigor211 study has been presented in abstract form and included 250 patients treated with VIN as part of a cohort patients with platinum-refractory metastatic UC receiving chemotherapy versus atezolizumab.[@b12-ce-13-001]

The objective of this study was to systematically amass all relevant publications to evaluate the efficacy of VIN in adult patients with UC in terms of response and survival rates as well as toxicity and tolerability of this therapy.

Methods
=======

Protocol registration
---------------------

Prior to the formal literature search, the protocol was prospectively registered at the International Prospective Register of Systematic Reviews, PROSPERO (registration CRD42016049294).

Study selection criteria
------------------------

To be eligible, retrieved articles had to include subjects (1) aged ≥18 years, (2) with a diagnosis of UC of the bladder, ureter, urethra, or renal pelvis, and (3) who were treated with systemic VIN chemotherapy. Studies that dealt primarily with animals or the treatment of non-urothelial malignancies were excluded. All studies, whether retrospective or prospective, whether randomized or not, were initially eligible, with the exception of single-patient case reports which were excluded. To be included in analyses, however, studies had to specifically report efficacy or toxicity outcomes for those subjects receiving VIN.

Search strategy for identification of studies
---------------------------------------------

The initial literature search was designed and executed by a medical information specialist (MVN). We searched MED-LINE^®^, Embase^®^, Cochrane Central Register of Controlled Trials, and Web of Science electronic databases through December 2016. The search captured terms for VIN and urinary bladder neoplasms using subject headings and text words. The search strategies are included in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D118670.pdf), [Appendix 1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D118670.pdf). Reference lists of included series were manually screened for any additional studies to minimize retrieval bias. All identified manuscripts and their citation information were imported into an electronic database.

Critical evaluation of the selected studies
-------------------------------------------

All manuscripts retrieved by the search strategy had their title and abstract prescreened by 2 of the researchers. Any reference deemed to potentially meet any of the inclusion criteria was tagged for full-text screening. A third reviewer adjudicated any prescreening discrepancies occurring between the first 2 reviewers. Full-text manuscripts were retrieved (where possible) for all prescreened abstracts, and these manuscripts were reviewed in detail by 2 researchers to determine if they met inclusion/exclusion criteria for the systematic review. In some instances, conference abstracts were identified without any discernible companion manuscript and such abstracts were retained if sufficient detail was present in the abstract for later data abstraction. No studies were excluded based on perceived quality or bias. Manuscripts (and in some instances abstracts) meeting screening criteria were then subject to data abstraction.

Data abstraction
----------------

Data elements were abstracted by 2 independent reviewers from the screened manuscripts and abstracts into an electronic database. Discrepancies in abstracted data were resolved by consensus review of the manuscript. All data were extracted directly from the manuscript or calculated from the available information when necessary. Clinical data including trial details, patient-specific data (age, sex, performance status), disease-specific data (tumor stage, tumor location, location of metastases, prior treatment, associated lab abnormalities), response data (complete response \[CR\], partial response \[PR\], stable disease, objective response rate, duration of response), survival outcomes, and toxicity outcomes were collected. The data on all trials were based on the intention-to-treat (ITT) principle whenever possible.

The primary efficacy outcomes analyzed were median PFS and OS, treatment response, and response duration. Response rates were generally reported according to RECIST criteria.[@b13-ce-13-001] In this system, progressive disease is defined as the development of new lesions or growth of existing lesions ≥20%; a CR indicates the complete disappearance of tumor; a PR indicates that the tumor has shrunk by ≥30% but is still visible on imaging; the objective response rate is the sum of the CR and PR rates; and stable disease is when tumor size shrinks by \<30% and grows by no more than 20%.

Safety outcome analysis included incidence, type, and (where possible) the Common Terminology Criteria for Adverse Events (CTCAE) severity of non-hematologic adverse events (AEs) (fatigue, nausea, vomiting, mucositis, abdominal pain, constipation, myalgia, neuropathy, alopecia, infusion-site reaction) and hematologic AEs (anemia, neutropenia, neutropenic fever, thrombocytopenia).[@b14-ce-13-001]

Analysis and presentation of results
------------------------------------

Abstracted data were cleaned and condensed. Trials that generated multiple publications were combined into a single consensus record per trial. This resulted in 29 total studies that contain data analyzable in our systematic review. When individual publications from the same trial had different outcome data, we selected the outcomes with 1) the longest median follow-up time and 2) the data from the publication describing the full set of subjects and toxicity outcomes (i.e., not subgroup publications) for inclusion in the consensus record.

Statistical analysis was done using R 3.4.2 "Short Summer" on RStudio 1.1.383. For pooling proportions, the meta package was used.[@b15-ce-13-001] Fixed effect (FE) and random effect (RE) models were constructed using inverse variance weighting. For variance stabilization, proportions were pooled after arcsine transformation,[@b16-ce-13-001] restricted maximum likelihood estimation was used to calculate the between-study variance (τ^2^) in the RE models, and pooled arcsine-transformed proportions and their 95% CIs were then back-transformed to the normal scale for presentation.[@b17-ce-13-001] CIs for individual study proportions were calculated using the Clopper--Pearson method. The presence of residual heterogeneity was assessed using the *I*^2^ statistic.[@b18-ce-13-001] Forest plots were created to visually demonstrate results. To measure and plot survival times across studies, individual Kaplan--Meier plots were extracted and digitized using the digitize package for R and plotted using ggplot2.[@b19-ce-13-001],[@b20-ce-13-001]

Results
=======

Search results
--------------

[Figure 1](#f1-ce-13-001){ref-type="fig"} presents the flow of identification and inclusion of articles as recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.[@b21-ce-13-001] Our initial search resulted in 381 publications after de-duplication. After title and abstract review, 198 publications were excluded, leaving 84 studies for full-text analysis. Upon full-text analysis, 50 additional publications were excluded for various reasons (28 were duplicate data sets or articles, 16 lacked VIN data, 3 did not involve UC, 2 were not available in English, and 1 was a review article). One trial, IMvigor211, was presented in abstract form after our planned inclusion date range, but was included because it was felt to be an important study and contained a large number of VIN-treated patients. This resulted in 35 publications from which data variables were abstracted, and characteristics of these studies are shown in [Table 1](#t1-ce-13-001){ref-type="table"}. The final analysis included 29 single consensus records for which data were available.

Chemotherapy with VIN
---------------------

A total of 2,255 subjects received systemic therapy with VIN for the treatment of UC. All patients had the American Join Committee on Cancer stage IV cancer, though not all were metastatic as some were locally advanced nonmetastatic patients. VIN standard dose was most commonly 320 mg/m^2^ every 21 days as a 20-minute infusion (reported in 17 of 28 included studies) with reduced doses of either 250 or 280 mg/m^2^ with similar administration schedule. The majority of VIN administration was as second-line therapy after platinum failure; however, studies included data on third-line, maintenance, and first-line combination therapy.[@b9-ce-13-001]--[@b11-ce-13-001],[@b22-ce-13-001]--[@b25-ce-13-001]

Response data
-------------

VIN chemotherapy response information was available from 17 studies, representing 1,416 patients. Forest plots for CR ([Figure 2](#f2-ce-13-001){ref-type="fig"}), PR ([Figure 3](#f3-ce-13-001){ref-type="fig"}), and overall response ([Figure 4](#f4-ce-13-001){ref-type="fig"}) are presented. There were few documented complete responders, and the pooled CR rate using FEs was 1% (95% CI 1--2%) and using REs was 1% (95% CI 1--3%), with an *I*^2^ of 75%. The pooled PR rate was 16% (95% CI 14--18%) using FEs and 18% (95% CI 14--22%) using REs, with an *I*^2^ of 72%. The pooled objective response rate with FEs was 18% (95% CI 16--20%) and with REs was 21% (95% CI 16--26%) with an *I*^2^ of 79%.

Survival analysis
-----------------

Kaplan--Meier curves were available for OS for 11 studies ([Figure 5](#f5-ce-13-001){ref-type="fig"}), and median OS ranged from 5.2 to 13.4 months.[@b11-ce-13-001],[@b26-ce-13-001] PFS was available for 6 studies ([Figure 6](#f6-ce-13-001){ref-type="fig"}) and ranged from 2.2 to 6.5 months.[@b10-ce-13-001],[@b27-ce-13-001]

Toxicity analysis
-----------------

AEs (overall and grade 3--4) associated with VIN treatment are summarized in [Table 2](#t2-ce-13-001){ref-type="table"} for non-hematologic events and [Table 3](#t3-ce-13-001){ref-type="table"} for hematological events. Forest plots for these are found in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D118670.pdf), [Appendix 2](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D118670.pdf). The most prevalent non-hematologic AEs according to pooled REs analysis including all CTCAE grades were fatigue (40.1%), nausea (33.9%), constipation (34.1%), and alopecia (26.0%). The most prevalent CTCAE grade 3--4 non-hematologic AEs were fatigue (10.2%), abdominal pain (8.2%), myalgias (2.5%), and nausea (2.3%). The most common hematological AEs were anemia (56.6%), neutropenia (46.0%), thrombocytopenia (25.5%), and febrile neutropenia (6.6%). Grade 3--4 hematologic AE rates were 24.6% for neutropenia, 10.2% for anemia, 5.4% for febrile neutropenia, and 3.0% for thrombocytopenia.

Discussion
==========

VIN has been evaluated in multiple trials as a first-line, second-line, third-line, and maintenance chemotherapeutic agent in the treatment of advanced and metastatic UC. The largest multinational study to date looking at VIN plus BSC versus BSC alone showed that VIN treatment as a second-line agent in platinum-refractory patients provides a 2.3-month improvement in median OS. With \>40 months of follow-up, this difference was not statistically significant in the ITT population (*p*=0.2613); however, analysis of the eligible population as well as a multivariate analysis showed a significant survival benefit. Importantly, in post hoc analyses of these data, a prognostic model was created which was validated in several other studies.[@b28-ce-13-001]--[@b30-ce-13-001] This treatment response model classifies patients into 4 risk categories based on the presence of 0, 1, 2, or 3 of the following risk factors: ECOG performance status (0 versus 1), liver metastases (present versus absent), and hemoglobin (\<10 versus ≥10 g/dl). In this study, median OS varied from 14.2 to 1.7 months depending on these risk factors, stressing the importance of patient selection in VIN as second-line therapy.

JASINT1 was the first study to examine first-line therapy doublets containing VIN in patients with good ECOG performance status (0/1) and impaired renal function making them ineligible for cisplatin. Significantly less grade 3--4 hematologic AEs were reported with VG versus VC with similar DCR, ORR, and OS.[@b11-ce-13-001] To date, there have been no efficacy comparison studies of VIN combinations to current standard of first-line alternatives to cisplatin-containing regimens. We suggest a comparison study with carboplatin combinations as a logical next step in assessing this treatment as we are unable to assess comparative survival statistics at this time.

VIN maintenance therapy after first-line cisplatin-based treatment was shown in the JASiMA trial as well as by A paricio et al to have an acceptable toxicity profile.[@b9-ce-13-001],[@b31-ce-13-001] Neutropenia, the most common AE, was reversible and noncumulative. The MAJA trial has shown favorable outcomes comparing VIN maintenance with BSC with 59% disease progression and 43% patient death in the treatment arm versus 81% and 62%, respectively, in the BSC control arm.[@b10-ce-13-001] Survival analysis in this trial is pending; however, this response benefit was demonstrated in the context of favorable tolerability.

Di Lorenzo et al evaluated third-line therapies including cyclophosphamide, platinum-containing regimens, paclitaxel, docetaxel, gemcitabine, and VIN in a total of 52 patients.[@b23-ce-13-001] In this setting, VIN showed inferior PFS and OS outcomes to cyclophosphamide as well as 18.75% higher absolute incidence of grade 3 and above AEs. Although a better powered study would be beneficial, it does seem from this preliminary data that VIN does not seem active as a third-line choice.

It is exceedingly important to consider the cost to the health care system with the introduction of any new treatment. Guglieri-Lopez et al performed an economic analysis of VIN, finding a median treatment cost of €8,524 per patient, a €44,789 per progression-free year gained, and €22,750 per life-year granted.[@b32-ce-13-001] We know that bladder cancer is the most expensive among cancer diagnoses per patient lifetime and carries annual costs of \$3.98 billion in the US.[@b33-ce-13-001],[@b34-ce-13-001] Although we are unable to directly compare this study to the cost-effectiveness data of other UC therapies, the high cost associated with VIN makes patient selection an extremely important factor, specifically when considering the modest survival benefit to patients in higher-risk categories.

As far as toxicity is concerned, VIN was associated with considerable rates of high-grade anemia and neutropenia. While these conditions can come at the cost of the need for dose reduction and even treatment termination, it is important to consider that these AEs are often preventable with appropriate prophylaxis, or are treatable and reversible.[@b35-ce-13-001],[@b36-ce-13-001] Data suggest that overall AEs may be correlated with increased efficacy of treatment.[@b37-ce-13-001]

Conclusion
==========

VIN has been explored as a combination first-line treatment as well as a single-agent second-line, third-line, and maintenance therapy in advanced and metastatic UC. In first-line treatment of UC, either as a maintenance agent after cisplatin or as a primary combination therapy, VIN may be a promising alternative to current treatments. Further studies are needed to compare first-line combination VIN regimens to the current standard of care in order to assess long-term survival outcomes. Second- and third-line VIN monotherapy does provide a proven, although limited, survival benefit in platinum-refractory patients.
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###### 

Study-level characteristics

  Author                                 Country of Origin   Year of Publication   Journal                         Centers         Blinding     Study Type       Sampling Frame   Study Start Date   Study End Date   Trial ID        No. Patients Vinflunine   Median Age   Male   Female   No. Patients Stage IV   Median Follow-up (months)
  -------------------------------------- ------------------- --------------------- ------------------------------- --------------- ------------ ---------------- ---------------- ------------------ ---------------- --------------- ------------------------- ------------ ------ -------- ----------------------- ---------------------------
  Aparicio et al[@b31-ce-13-001]         Spain               2013                  European Journal of Cancer      multicenter     open label   case series      Retrospective                                                        10                                                     10                      10.5
  Bamias et al[@b38-ce-13-001]           Greece              2016                  Clinical Genitourinary Cancer   multicenter     open label   case series      Retrospective    1/1/2011           12/31/2013       HGUCG           36                        68           31     5        36                      16.8
  Bellmunt et al[@b28-ce-13-001]         Spain               2010                  J Clin Oncol                    multicenter     open label   RCT              Prospective      5/15/2003          8/15/2006        L00070 IN 302   253                       64           292    78       370                     
  Bellmunt et al[@b7-ce-13-001]          Spain               2013                  Ann Oncol                       multicenter     open label   RCT              Prospective      5/15/2003          8/15/2006        L00070 IN 302   253                       64                                                   42.9
  Bellmunt et al[@b8-ce-13-001]          Spain               2009                  J Clin Oncol                    multicenter     open label   RCT              Prospective      5/15/2003          8/15/2006        L00070 IN 302   253                       64                                                   
  Bellmunt et al[@b22-ce-13-001]         Spain               2015                  Journal                         multicenter     open label   RCT              Prospective      4/15/2012          1/15/2015        MAJA            33                        63                                                   7.2
  Castellano et al[@b35-ce-13-001]       Spain               2014                  BMC Cancer                      multicenter     open label   case series      Retrospective    12/15/2009         6/15/2013                        102                       67                           102                     8.9
  Chirivella et al[@b39-ce-13-001]       Spain               2013                  European Journal of Cancer      multicenter     open label   case series      Retrospective    4/15/2010          12/15/2012                       45                        68                                                   
  Culine et al[@b5-ce-13-001]            UK                  2006                  Br J Cancer                     multicenter     open label   phase II trial   Prospective      11/15/2000         9/15/2002                        51                        63           41     17       58                      
  De Santis et al[@b11-ce-13-001]        Austria             2016                  Ann Oncol                       multicenter     open label   phase II trial   Prospective      2/15/2011          8/15/2012        JASINT1         69                        70                           69                      25.9
  De Wit et al[@b9-ce-13-001]            Germany             2015                  European Journal of Cancer      multicenter     open label   phase II trial   Prospective      2/15/2012          7/15/2013        JASiMA          19                                                                             9
  Di Lorenzo et al[@b23-ce-13-001]       Italy               2015                  Medicine (Baltimore)            multicenter     open label   case series      Retrospective    1/15/2010          1/15/2015                        10                                                     52                      
  Di Palma et al[@b29-ce-13-001]         France              2013                  European Journal of Cancer      multicenter     open label   case series      Retrospective    11/15/2012         2/15/2013        CURVE           134                                                                            
  Donini et al[@b40-ce-13-001]           Italy               2015                  Annals of Oncology              multicenter     open label   case series      Retrospective    2/15/2011          6/15/2014        MOVIE           84                        72           71     13       84                      
  Facchini et al[@b27-ce-13-001]         Italy               2016                  Front Pharmacol                 single center   open label   case series      Retrospective    2/15/2012          3/15/2015                        43                        63.5         40     3        43                      24
  Font et al[@b10-ce-13-001]             Spain               2016                  Journal of Clinical Oncology    multicenter     open label   RCT              Prospective      4/15/2012          1/15/2015        MAJA            45                        64                           88                      12.2
  George et al[@b41-ce-13-001]           USA                 2007                  Ejc Supplements                 multicenter     open label   phase II trial   Prospective                                                          114                       66           88     26                               
  Gerullis et al[@b42-ce-13-001]         Germany             2013                  Anticancer Drugs                single center   open label   phase I trial    Prospective      5/15/2011          12/15/2011       NCT01265940     5                         72           5      0        5                       
  Guglieri-Lopez et al[@b32-ce-13-001]   Spain               2015                  Anticancer Drugs                multicenter     open label   Cohort           Retrospective    3/15/2010          11/15/2013                       37                        67           36     1                                37
  Harshman et al[@b30-ce-13-001]         USA                 2013                  Br J Cancer                     multicenter     open label   RCT              Prospective      5/15/2003          8/15/2006        L00070 IN 302   253                       64           279    91       370                     45.4
  Hegele et al[@b43-ce-13-001]           Germany             2015                  Journal of Clinical Oncology    multicenter     open label   case series      Prospective                                                          77                                                                             
  Hegele et al[@b44-ce-13-001]           Germany             2014                  Urol Int                        multicenter     open label   case series      Retrospective    2/15/2010          3/15/2012                        21                        63           19     2        21                      
  Holmsten et al[@b45-ce-13-001]         Sweden              2016                  Oncol Lett                      multicenter     open label   case series      Retrospective    2/15/2010          7/15/2013                        100                       68           72     28       100                     
  Houede et al[@b46-ce-13-001]           France              2016                  BMC Cancer                      multicenter     open label   case series      Ambispective     4/15/2013          4/15/2014                        72                        68           183    35                               
  Hussain et al[@b47-ce-13-001]          UK                  2015                  European Journal of Cancer      multicenter     open label   case series      Retrospective                                                        37                        64           24     13       37                      
  Marongiu et al[@b24-ce-13-001]         Italy               2013                  European Urology, Supplements   multicenter     open label   case series      Retrosective     1/1/2001           12/31/2013                       40                        67                           40                      
  Medioni et al[@b36-ce-13-001]          Italy               2016                  BMC Cancer                      multicenter     open label   case series      Retrosective     1/1/2011           12/31/2011                       134                       65.3         119    15       134                     17.6
  Moriceau et al[@b48-ce-13-001]         France              2015                  Clin Genitourin Cancer          single center   open label   case series      Retrospective    5/15/2010          3/15/2014                        19                        66           18     1        19                      
  Palacka et al[@b26-ce-13-001]          Slovak Republic     2014                  Klin Onkol                      single center   open label   case series      Prospective      4/15/2011          6/15/2014                        16                        62           13     3        16                      5.2
  Passalacqua et al[@b49-ce-13-001]      Italy               2016                  Journal of Clinical Oncology    multicenter     open label   case series      Retrospective    2/15/2011          6/15/2014        MOVIE           217                       69           182    35       217                     
  Pistamaltzian et al[@b50-ce-13-001]    Greece              2016                  Anticancer Drugs                multicenter     open label   case series      Retrospective    7/15/2005          7/15/2014                        71                        66.8         65     6                                11.8
  Polo et al[@b25-ce-13-001]             Spain               2014                  Journal of Clinical Oncology    multicenter     open label   RCT              Prospective      4/15/2012          9/15/2013        MAJA            20                        65.6                         46                      
  Powles et al[@b12-ce-13-001]           UK                  2017                  EAS Meeting                     multicenter     open label   RCT              Prospective      1/13/2015          3/13/2017        IMvigor211      250                       67           195    55       233                     17.3
  Retz et al[@b51-ce-13-001]             Germany             2015                  BMC Cancer                      multicenter     open label   case series      Prospective      8/15/2010          9/15/2011        NCT01103544     77                        67           63     14       77                      4.6
  Vaughn et al[@b6-ce-13-001]            USA                 2009                  Cancer                          multicenter     open label   phase II trial   Prospective                                                          151                       66           121    30       151                     11.9

**Abbreviations:** RCT, randomized controlled trial; VIN, vinflunine.

###### 

Non-hematologic adverse events of all CTCAE grades and grade 3--4

  Non-hematologic adverse events   Number of subjects (N)   Number of studies (k)   *I*^2^   Fixed effect   95% CI         Random effect   95% CI
  -------------------------------- ------------------------ ----------------------- -------- -------------- -------------- --------------- --------------
  **Adverse event (overall)**                                                                                                              
  Fatigue                          1,000                    10                      93.9     0.426          0.395--0.456   0.401           0.276--0.533
  Nausea                           715                      7                       82.1     0.357          0.323--0.393   0.339           0.252--0.432
  Constipation                     1,112                    12                      96.7     0.31           0.283--0.337   0.341           0.207--0.489
  Alopecia                         416                      4                       71.5     0.273          0.232--0.317   0.26            0.163--0.371
  Infusion-site reaction           508                      5                       95.6     0.257          0.220--0.296   0.34            0.023--0.789
  Vomiting                         854                      9                       90.4     0.249          0.220--0.278   0.219           0.128--0.326
  Mucositis                        644                      6                       87.3     0.212          0.181--0.244   0.184           0.099--0.289
  Abdominal pain                   917                      9                       84.1     0.178          0.154--0.203   0.168           0.101--0.247
  Myalgias                         567                      5                       8.8      0.154          0.125--0.185   0.154           0.125--0.185
  Neuropathy                       805                      7                       92.5     0.151          0.127--0.177   0.157           0.071--0.271
  **Adverse event (grade 3--4)**                                                                                                           
  Fatigue                          1,381                    14                      91.3     0.113          0.097--0.131   0.102           0.053--0.164
  Constipation                     1,631                    19                      76.9     0.086          0.073--0.100   0.082           0.056--0.113
  Abdominal pain                   1,025                    10                      56.9     0.047          0.035--0.061   0.046           0.028--0.070
  Myalgias                         667                      6                       4.7      0.025          0.015--0.038   0.025           0.015--0.038
  Nausea                           870                      10                      42.4     0.023          0.014--0.034   0.023           0.011--0.038
  Vomiting                         972                      11                      40.1     0.023          0.014--0.033   0.022           0.012--0.036
  Mucositis                        773                      9                       56.2     0.02           0.011--0.031   0.02            0.006--0.041
  Neuropathy                       974                      10                      81.7     0.015          0.008--0.024   0.018           0.002--0.048
  Infusion-site reaction           598                      5                       64       0.007          0.002--0.016   0.007           0.000--0.025

**Abbreviation:** CTCAE, Common Terminology Criteria for Adverse Events.

###### 

Hematologic adverse events of all CTCAE grades and grade 3--4

  Hematologic adverse events       Number of subjects (N)   Number of studies (k)   *I*^2^   Fixed effect   95% CI         Random effect   95% CI
  -------------------------------- ------------------------ ----------------------- -------- -------------- -------------- --------------- --------------
  **Adverse event (overall)**                                                                                                              
  Anemia                           1,058                    12                      98.4     0.653          0.624--0.681   0.546           0.299--0.782
  Neutropenia                      1,058                    12                      97.6     0.513          0.483--0.543   0.46            0.273--0.654
  Thrombocytopenia                 1,037                    11                      96.8     0.298          0.271--0.326   0.255           0.125--0.412
  Febrile neutropenia              815                      8                       70.4     0.06           0.045--0.078   0.066           0.033--0.110
  **Adverse event (grade 3--4)**                                                                                                           
  Neutropenia                      1,521                    18                      94.3     0.264          0.242--0.286   0.246           0.165--0.338
  Anemia                           1,222                    15                      86.5     0.115          0.098--0.133   0.102           0.059--0.154
  Febrile neutropenia              995                      12                      38.6     0.055          0.042--0.070   0.054           0.035--0.076
  Thrombocytopenia                 1,073                    11                      69.6     0.032          0.022--0.043   0.03            0.013--0.054

**Abbreviation:** CTCAE, Common Terminology Criteria for Adverse Events.
